Centers of Excellence
The William S. Rowe Division of Rheumatology at Cincinnati Children's Hospital Medical Center is involved in numerous cutting-edge research projects to better our understanding of pediatric rheumatic diseases.
The Division of Rheumatology at Cincinnati Children's Hospital Medical Center is focused on studying rheumatic diseases of childhood. In keeping with this tradition, the goals of the Cincinnati Rheumatic Diseases Core Center are to promote and foster cutting-edge research that will further the understanding of the pathophysiologies of the rheumatic diseases and lead to novel therapeutic approaches to the treatment of these diseases and change the outcome for children suffering from them.
For more information about this study, contact Susan Thompson, PhD.
NIAMS P-60: Multidisciplinary Clinical Research Center (MCRC): To Provide Needed Expertise for the Division of Rheumatology That Are not Available at the Laboratory Level
The Multidisciplinary Clinical Research Center provides resources to the division of Rheumatology and the research base that would be impossible for any single laboratory to provide on their own. These services have markedly and positively impacted on the growth of Rheumatology in both Cincinnati Children's and in the Close collaborations within the MCRC, and collaboration of the MCRC with other researchers and organizations as well as the MCRC Research Base have worked synergistically to promote research in pediatric rheumatology. As a result the Division of Rheumatology has expanded substantially as a result of the award of the P60 Centers and this expansion is particularly notable in terms of faculty, papers, grant support and fellows.
For more information about this study, contact David N. Glass, MD.
NIAMS Registry: To Identify Specific Families for Research Purposes
This JRA-affected sib-pair registry, sponsored by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) (an Institute of the US National Institutes of Health), is a unique and powerful resource for investigators seeking to understand the causes and outcomes of JRA. Collaborative and synergistic use of Registry resources are encouraged as a route to more effective research into the causes of JRA and improvement of treatment.
For more information about this study, contact Sandy Kramer (sandy.kramer@cchmc.org), or David N. Glass, MD.
NIAMS P-01: To Identify Gene Expression Patterns to Use as New Markers of Disease
The level of mRNA of all genes in blood cells will be measured by microarray analysis to identify patterns specific to: JRA patients, specific JRA subtypes, response to treatment, or outcome variables. These expression markers may provide a molecular basis for treatment decisions at early stages of disease.
For more information about this study
, contact Robert A. Colbert, MD, PhD, or David N. Glass, MD. NIAMS Contract: To Identify the Genetic Components of JRA
JRA is the most common chronic inflammatory pediatric rheumatic disease with about 80,000 cases in the United States alone. This autoimmune disease is categorized as a complex genetic trait. Genetic studies have identified both HLA and non-HLA candidate genes and several chromosome regions for potential contribution to either JRA susceptibility or resistance. Together, the existing collection of DNA from the JRA Affected Sib Pair Registry (more than 200 families) and a cohort of more than 1,300 simplex JRA families, the developments of the Human Genome Project, the HapMap Project and technical advances in SNP genotyping make this project possible.
For more information about this study, contact David N. Glass, MD, or Susan Thompson, PhD.
NIAMS R-01: Genomic Landscapes in Large Scale Integrated JRA Studies
Integration of traditional genetic datasets with genome scale expression datasets will lead to the ability to better predict course of disease and response to treatment for patients with JRA. This project will develop new algorithms to analyze the data from these disparate but complementary technologies.
For more information about this study, contact Susan Thompson, PhD.
